146 related articles for article (PubMed ID: 36733146)
21. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
Dominici LS; Negron Gonzalez VM; Buzdar AU; Lucci A; Mittendorf EA; Le-Petross HT; Babiera GV; Meric-Bernstam F; Hunt KK; Kuerer HM
Cancer; 2010 Jun; 116(12):2884-9. PubMed ID: 20564395
[TBL] [Abstract][Full Text] [Related]
22. [A patient with primary breast cancer who responded remarkably well to neoadjuvant chemotherapy with FEC100 followed by Abraxane].
Yoshibayashi H; Ishiguro H; Kawaguchi K; Yamoto M; Nishimura T; Yamada H; Namura M; Nishio N; Nakamura K; Shimada K; Ono K; Kato H
Gan To Kagaku Ryoho; 2013 May; 40(5):627-9. PubMed ID: 23863587
[TBL] [Abstract][Full Text] [Related]
23. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
25. [A Case of Metaplastic Squamous Cell Carcinoma of the Breast Diagnosed after Neoadjuvant Chemotherapy].
Ishikawa N; Saimura M; Koga K; Anan K; Mitsuyama S; Tamiya S
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1101-1103. PubMed ID: 30042281
[TBL] [Abstract][Full Text] [Related]
26. [A Case of Bilateral HER2-Positive Invasive Ductal Carcinoma with Complete Response on One Side with Trastuzumab Deruxtecan].
Miyazaki S; Iwasaki K; Narita T; Yoneda G; Takei H; Jibiki N
Gan To Kagaku Ryoho; 2023 Mar; 50(3):327-331. PubMed ID: 36927901
[TBL] [Abstract][Full Text] [Related]
27. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
28. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
29. De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Nitz U; Gluz O; Graeser M; Christgen M; Kuemmel S; Grischke EM; Braun M; Augustin D; Potenberg J; Krauss K; Schumacher C; Forstbauer H; Reimer T; Stefek A; Fischer HH; Pelz E; Zu Eulenburg C; Kates R; Wuerstlein R; Kreipe HH; Harbeck N;
Lancet Oncol; 2022 May; 23(5):625-635. PubMed ID: 35405088
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Im SA; Lee KS; Ro J; Lee ES; Kwon Y; Ahn JH; Ahn JS; Kim JH; Kang HS; Shin KH; Noh DY; Park IA; Kim SB; Im YH; Ha SW
Breast Cancer Res Treat; 2012 Apr; 132(2):589-600. PubMed ID: 22094934
[TBL] [Abstract][Full Text] [Related]
31. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
32. [A Case of Locally-Advanced Breast Cancer with Liver Metastasis, Treated with Mastectomy of the Primary Tumor after Chemotherapy].
Kanada Y; Matsuzaki H; Kobayashi H; Suzuki K; Sawada H; Senba Y; Yoshioka T; Note H; Sato Y; Miyazaki A; Natsume T; Tanaka H; Maruyama T
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1509-11. PubMed ID: 26805079
[TBL] [Abstract][Full Text] [Related]
33. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
34. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274
[TBL] [Abstract][Full Text] [Related]
35. [A Case of HER2-Positive Metastatic Breast Cancer Achieved a Complete Response to Paclitaxel and Trastuzumab in Combination with Pertuzumab in Fifth Therapy].
Mimata A; Yoshitomi S; Morikawa N; Hara K; Tsuji H
Gan To Kagaku Ryoho; 2021 Feb; 48(2):263-265. PubMed ID: 33597376
[TBL] [Abstract][Full Text] [Related]
36. The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant Chemotherapy.
Flores-Balcázar CH; Castro-Alonso FJ; Hernández-Barragán TP; Delgado-de la Mora J; Daidone A; Trejo-Durán GE
Oncology (Williston Park); 2021 Mar; 35(3):139-143. PubMed ID: 33818049
[TBL] [Abstract][Full Text] [Related]
37. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
[TBL] [Abstract][Full Text] [Related]
38. [A case of breast adenocarcinoma changed to squamous cell carcinoma after neoadjuvant chemotherapy].
Minagawa M; Kanzaki M; Takano Y; Nishikawa T; Deie K; Minami Y; Maeda M; Teshima S
Gan To Kagaku Ryoho; 2012 Jul; 39(7):1111-4. PubMed ID: 22790049
[TBL] [Abstract][Full Text] [Related]
39. [Two Cases of Advanced HER2-Positive Locally Advanced Breast Cancer for Which Preoperative Chemotherapy with Pertuzumab, Trastuzumab, and Docetaxel Resulted in Good Response].
Ishiyama T; Yamaya H; Jinguu A; Matsumoto H
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1505-1507. PubMed ID: 33130751
[TBL] [Abstract][Full Text] [Related]
40. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
